STOCK TITAN

AbbVie (ABBV) director Meyer granted 1,118 restricted stock units as equity pay

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MEYER MELODY B reported acquisition or exercise transactions in this Form 4 filing.

AbbVie Inc. director Melody B. Meyer received an award of 1,118 shares of common stock in the form of restricted stock units. These units were granted at no cash cost to her and increase her directly owned holdings to 17,616 shares.

The restricted stock units were granted under the AbbVie Amended and Restated 2013 Incentive Stock Program and will be settled on a one-to-one basis in AbbVie common stock upon the earlier of her separation from service, death, or a change in control as defined in the program.

Positive

  • None.

Negative

  • None.
Insider MEYER MELODY B
Role null
Type Security Shares Price Value
Grant/Award Common Stock, $0.01 par value 1,118 $0.00 --
Holdings After Transaction: Common Stock, $0.01 par value — 17,616 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Restricted stock units granted 1,118 shares Equity award to director Melody B. Meyer
Shares owned after transaction 17,616 shares Total AbbVie common stock directly held by Meyer
Grant price per share $0.0000 per share Indicates a non-cash equity award
restricted stock units financial
"These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
AbbVie Amended and Restated 2013 Incentive Stock Program financial
"awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program")"
change in control financial
"on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MEYER MELODY B

(Last)(First)(Middle)
1 N. WAUKEGAN ROAD

(Street)
NORTH CHICAGO ILLINOIS 60064

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock, $0.01 par value05/08/2026A1,118(1)A$017,616D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
/s/ T.O. Odutayo, Attorney-in-Fact for Melody B. Meyer05/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did AbbVie (ABBV) director Melody B. Meyer report?

AbbVie director Melody B. Meyer reported receiving 1,118 restricted stock units. These represent a compensation-related grant of AbbVie common stock, not an open-market purchase or sale, and are awarded under the company’s incentive stock program.

How many AbbVie (ABBV) shares does Melody B. Meyer hold after this Form 4?

After the reported grant, Melody B. Meyer directly owns 17,616 AbbVie shares. This total includes the newly awarded 1,118 restricted stock units, which are structured to convert into common stock under specific future conditions.

What type of award did AbbVie (ABBV) grant to Melody B. Meyer?

Melody B. Meyer received restricted stock units tied to AbbVie common stock. These units were granted under the AbbVie Amended and Restated 2013 Incentive Stock Program as a form of non-cash equity compensation for her role as a director.

When will Melody B. Meyer’s AbbVie (ABBV) restricted stock units be paid out?

The restricted stock units will be paid on a one-to-one basis in AbbVie common stock. Payment occurs upon the earlier of Meyer’s separation from service, her death, or a change in control, as defined in AbbVie’s incentive stock program.

Did Melody B. Meyer buy or sell AbbVie (ABBV) shares on the market?

The Form 4 shows a grant of 1,118 restricted stock units, not a market trade. The transaction is classified as a grant or award acquisition, meaning it reflects equity compensation rather than an open-market purchase or sale of shares.